4’-(1-吡咯烷基)苯乙酮 | 21557-09-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4’-(1-吡咯烷基)苯乙酮
• 中文别名: 4'-(1-吡咯烷基)苯乙酮；4-(1-吡咯烷)苯乙酮
• 英文名称: N-(4-acetylphenyl)pyrrolidine
• 英文别名: 1-(4-(pyrrolidin-1-yl)phenyl)ethan-1-one；1-(4-(pyrrolidin-1-yl)phenyl)ethanone；1-(4-Pyrrolidin-1-ylphenyl)ethanone
• CAS: 21557-09-5
• 化学式: C₁₂H₁₅NO
• mdl: MFCD01075691
• 分子量: 189.257
• InChiKey: WNRFELFKDNNURJ-UHFFFAOYSA-N

物化性质

• 熔点：
  129-131°C
• 沸点：
  342.7±25.0 °C(Predicted)
• 密度：
  1.078±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解。避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  保持贮藏器密封，并将其放入一个紧密封装的容器中。存放在阴凉、干燥的地方。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4’-(1-Pyrrolidino)acetophenone
Product Name:
Synonyms: 1-(4-(Pyrrolidin-1-yl)phenyl)ethanone

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4’-(1-Pyrrolidino)acetophenone
Ingredient name:
CAS number: 21557-09-5

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H15NO
Molecular weight: 189.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4’-(1-吡咯烷基)苯乙酮 在 N-溴代丁二酰亚胺(NBS) 、 对甲苯磺酸 作用下， 以 水 、 乙腈 为溶剂， 生成 2-溴-4’-(1-吡咯烷基)苯乙酮
  参考文献：
  名称：

  核独立化学位移 (NICS) 作为新抗真菌苯并呋喃酮设计的标准

  摘要：

  吴等人的断言。芳香性可能对分子设计有相当大的影响，促使我们使用核独立化学位移 (NICS) 作为芳香性标准来评估两个系列的 indol-4-one 的抗真菌活性。NICS 和抗真菌活性的线性回归分析表明，两个测试变量显着相关（p< 0.05); 当芳香性增加时，系列 I 的抗真菌活性降低，系列 II 的抗真菌活性增加。为了验证所得到方程的有效性，通过用氧取代 indol-4-ones 中的五元环的氮原子，设计了一组新的 44 benzofuran-4-ones。计算了苯并呋喃-4-酮的 NICS(0) 和 NICS(1)，并使用前面的方程来预测它们的生物活性。一组 10 苯并呋喃 4-ones 合成并在八种人类致病真菌中进行测试，显示了方程的有效性。对于光滑念珠菌、克柔念珠菌和吉列念珠菌与化合物15 -酵母菌的最低抑菌浓度 (MIC) 为 31.25 µg·mL –132，15 - 15和15

  DOI：

  10.3390/molecules26165078
• 作为产物：
  描述：

  1-(4-(二烯丙基氨基)苯基)乙酮 在 Grubbs catalyst first generation 、 氢气 、 铁粉 作用下， 以 甲醇 为溶剂， 反应 10.0h， 以71%的产率得到4’-(1-吡咯烷基)苯乙酮
  参考文献：
  名称：

  一种金属催化下的串联合成苯基吡咯烷衍生物的制备方法

  摘要：

  本发明涉及一种金属催化下的串联合成苯基吡咯烷衍生物的制备方法。所制备的苯基吡咯烷衍生物结构式如附图1所示。制备方法：N,N‑二烯丙基苯胺类化合物，Grubbs催化剂、还原铁粉以及反应溶剂，反应温度设定为40 oC、氢气氛围下充分搅拌反应8‑10小时。TLC监测反应结束后进行淬灭，用有机溶剂萃取，干燥，过滤，浓缩，柱层析提纯，得到苯基吡咯烷衍生物，产率在62～81%。本发明使用一锅法串联合成苯基吡咯烷衍生物，原料易得，操作简单，重复性好，而且反应条件温和、适合工业化生产。

  公开号：

  CN111620839B

文献信息

• Enantiodivergent α-Amino C–H Fluoroalkylation Catalyzed by Engineered Cytochrome P450s
  作者：Juner Zhang、Xiongyi Huang、Ruijie K. Zhang、Frances H. Arnold

  DOI：10.1021/jacs.9b04344

  日期：2019.6.26

  engineered cytochrome P450 enzymes to catalyze this abiological reaction under mild conditions with total turnovers (TTN) up to 4070 and enantiomeric excess (ee) up to 99%. The iron-heme catalyst is fully genetically encoded and configurable by directed evolution so that just a few mutations to the enzyme completely inverted product enantioselectivity. These catalysts provide a powerful method for synthesis

  将氟烷基引入有机化合物可以显着改变药理特性。由于有机分子中 CH 键的普遍存在，一种用于安装氟烷基的可行但尚未探索的方法是选择性 C(sp3)-H 官能化。我们设计了血红素酶，可以将氟烷基卡宾中间体插入 α-氨基 C(sp3)-H 键，并能够对含氟烷基的分子进行对映发散合成。使用定向进化，我们设计了细胞色素 P450 酶以在温和条件下催化这种非生物反应，总转化率 (TTN) 高达 4070，对映体过量 (ee) 高达 99%。铁血红素催化剂是完全遗传编码的，可通过定向进化进行配置，因此酶的少量突变即可完全逆转产物的对映选择性。这些催化剂为合成手性有机氟分子提供了一种强有力的方法，而小分子催化剂目前无法实现这一点。
• Practical heterogeneous photoredox/nickel dual catalysis for C–N and C–O coupling reactions
  作者：Yi-Yin Liu、Dong Liang、Liang-Qiu Lu、Wen-Jing Xiao

  DOI：10.1039/c9cc00987f

  日期：——

  Efficient C–N and C–O coupling reactions of aryl halides with amines and alcohols have been developed by using the strategy of heterogeneous visible light photoredox and nickel dual catalysis. Obviously, the joint use of inexpensive and bench-stable CdS and nickel salts, together with mild reaction conditions, makes these two transformations attractive for the synthetic community. This heterogeneous

  芳烃卤化物与胺和醇的高效C–N和C–O偶联反应已经通过使用非均相可见光光氧化还原和镍双重催化的策略得到了发展。显然，廉价，稳定的CdS和镍盐的结合使用以及适度的反应条件，使这两种转化对合成社区具有吸引力。这种非均相双重催化体系还证明了在以水为亲核试剂的情况下芳基溴化物的无配体催化羟基化反应是成功的。规模化反应和非均相光催化剂的可重复使用性进一步强调了该协议的实用性。
• [EN] 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE<br/>[FR] COMPOSÉS 1-(AZO-HÉTÉROCYCLE À 6 CHAÎNONS)-PYRROLIN-2-ONE COMME INHIBITEURS DE POLYMÉRASE NS5B D'HÉPATITE C, LEUR COMPOSITION PHARMACEUTIQUE ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：VIVALIS

  公开号：WO2011004017A1

  公开（公告）日：2011-01-13

  The present invention concerns a l-(6 members azo-heterocyclic)-pyrrolin-2-one compound of the following formula I or a salt, solvate, tautomer, isotope, enantiomer, diastereoisomer or racemic mixture thereof: the pharmaceutical composition thereof and their therapeutic use as inhibitors of Hepatitis C NS5B polymerase.

  本发明涉及以下式I的l-(6成员偶氮杂环)-吡咯烷-2-酮化合物或其盐、溶剂合物、互变异构体、同位素、对映体、非对映异构体或其外消旋混合物：以及其药物组合物及作为丙型肝炎NS5B聚合酶抑制剂的治疗用途。
• Asymmetric Reduction of Electron-Rich Ketones with Tethered Ru(II)/TsDPEN Catalysts Using Formic Acid/Triethylamine or Aqueous Sodium Formate
  作者：Rina Soni、Thomas H. Hall、Benjamin P. Mitchell、Matthew R. Owen、Martin Wills

  DOI：10.1021/acs.joc.5b00990

  日期：2015.7.2

  The asymmetric transfer hydrogenation (ATH) of ketones under aqueous conditions using tethered Ru(II)/η6-arene/diamine catalysts is described, as is the ATH of electron-rich substrates containing amine and methoxy groups on the aromatic rings. Although such substrates are traditionally challenging ones for ATH, the tethered catalysts work very efficiently. In the case of amino-substituted ketones,

  使用系留的Ru（II）水性条件/η下酮的不对称转移氢化（ATH）6 -arene /二胺的催化剂被描述，如为含有芳环胺和甲氧基富电子基板的ATH。尽管此类底物在传统上是ATH面临的挑战，但束缚催化剂的工作效率却很高。对于氨基取代的酮，在水性条件下可获得优异的结果。但是，对于甲氧基取代的底物，更完善的甲酸/三乙胺体系可提供更好的结果。
• Nickel‐Catalyzed Amination of (Hetero)aryl Halides Facilitated by a Catalytic Pyridinium Additive
  作者：Dongyang Han、Sasa Li、Siqi Xia、Mincong Su、Jian Jin

  DOI：10.1002/chem.202002800

  日期：2020.9.25

  An efficient and operationally simple Ni‐catalyzed amination protocol has been developed. This methodology features a simple NiII salt, an organic base and catalytic amounts of both a pyridinium additive and Zn metal. A diverse number of (hetero)aryl halides were coupled successfully with primary and secondary alkyl amines, and anilines in good to excellent yields. Similarly, benzophenone imine gave

  已经开发了有效且操作简单的镍催化胺化方案。该方法具有简单的Ni II盐，有机碱以及催化量的吡啶鎓添加剂和Zn金属的特征。多种（杂）芳基卤化物与伯，仲烷基胺和苯胺成功偶联，收率良好。同样，二苯甲酮亚胺以优异的收率得到了相应的N芳基化产物。